Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $36.45.

Several equities research analysts have commented on ASND shares. Wedbush reaffirmed an “outperform” rating and issued a $10.71 price target (down from $65.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Bank of America reaffirmed a “buy” rating and issued a $36.00 price target (up from $34.00) on shares of Ascendis Pharma A/S in a report on Monday, September 25th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $50.00 price target (up from $30.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Wells Fargo & Company reaffirmed a “buy” rating and issued a $51.00 price target on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Finally, Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd.

Several hedge funds have recently bought and sold shares of the company. RA Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 3.2% during the 2nd quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock worth $154,920,000 after acquiring an additional 170,700 shares in the last quarter. EcoR1 Capital LLC boosted its stake in shares of Ascendis Pharma A/S by 44.5% during the 2nd quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock worth $41,157,000 after acquiring an additional 456,900 shares in the last quarter. VHCP Management II LLC boosted its stake in shares of Ascendis Pharma A/S by 31.7% during the 3rd quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock worth $47,091,000 after acquiring an additional 312,560 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $15,403,000. Finally, First Manhattan Co. purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $12,881,000. 78.93% of the stock is currently owned by institutional investors and hedge funds.

Ascendis Pharma A/S (NASDAQ ASND) traded down $0.19 during trading hours on Monday, reaching $36.91. 76,340 shares of the company’s stock traded hands, compared to its average volume of 147,269. Ascendis Pharma A/S has a one year low of $19.21 and a one year high of $42.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative net margin of 4,687.42% and a negative return on equity of 64.10%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.78 million. During the same period in the previous year, the company posted ($0.53) earnings per share. Ascendis Pharma A/S’s revenue for the quarter was down 61.4% compared to the same quarter last year. equities research analysts anticipate that Ascendis Pharma A/S will post -3.65 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Ascendis Pharma A/S (ASND) Target Price at $36.45” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/12/02/brokerages-set-ascendis-pharma-as-asnd-target-price-at-36-45.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.